C

    Cartesian Therapeutics Inc. (RNAC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.28
    -0.32 (-3.33%)

    Market Cap: $290.45M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    55%(22/40)
    Avg Surprise
    -44.67%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.01
    Range$-1.01 - $-1.01
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.56+44.6%
    60d ago$-0.69+31.7%
    30d ago$-0.69+31.7%
    7d ago$-0.69+31.7%
    Current$-1.01
    Revenue Consensus
    $121430
    Range$0 - $300000
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.42
    Range$-0.42 - $-0.42
    1 analysts
    Revenue Consensus
    $-53210
    Range$-354460 - $567540
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.42---
    Sep 26EST
    		-$-1.01---
    Jun 26
    Reported Aug 6
    		$0.46$-0.83+155.42%Beat-8.0%
    Mar 26
    Reported Apr 30
    		$-0.95$-0.70-35.71%Miss-46.2%
    Dec 25
    Reported Mar 9
    		$-2.71$-0.79-242.59%Miss-356.0%
    Sep 25
    Reported Nov 6
    		$-0.73$-0.63-15.87%Miss-73.8%
    Jun 25
    Reported Aug 7
    		$0.50$-0.76+165.79%Beat-21.9%
    Mar 25
    Reported May 8
    		$-0.65$-0.71+8.45%Beat+18.8%
    Dec 24
    Reported Mar 20
    		$-0.59$-0.83+28.12%Beat-747.9%
    Sep 24
    Reported Nov 7
    		$-0.42$-0.55+23.64%Beat-600.0%
    Jun 24
    Reported Aug 8
    		$0.64$-0.09+811.11%Beat+1014.3%
    Mar 24
    Reported May 8
    		$-0.80$-1.42+43.66%Beat-471.4%
    Dec 23
    Reported Mar 7
    		$-0.07$-0.04-75.00%Miss-275.0%
    Sep 23
    Reported Nov 13
    		$-0.06$-0.06+0.00%Beat-20.0%
    Jun 23
    Reported Aug 17
    		$-0.07$-0.08+12.50%Beat-216.7%
    Mar 23
    Reported May 4
    		$-0.14$-0.09-55.56%Miss-160.9%
    Dec 22
    Reported Mar 30
    		$0.04$-0.07+157.14%Beat+33.3%
    Sep 22
    Reported Dec 29
    		$-0.05$-0.01-400.00%Miss+68.8%
    Jun 22
    Reported Sep 28
    		$0.06$-0.08+175.00%Beat+50.0%
    Mar 22
    Reported Jun 28
    		$0.23$-0.11+309.09%Beat+204.5%
    Dec 21
    Reported Mar 29
    		$0.03N/A+142.86%Beat+121.4%
    Sep 21
    Reported Dec 29
    		$-0.16$-0.07-128.57%Miss-77.8%
    Jun 21
    Reported Sep 28
    		$0.04N/A+133.33%Beat+116.0%
    Mar 21
    Reported Jun 28
    		$-0.22$-0.12-83.33%Miss-4.8%
    Dec 20
    Reported Mar 29
    		$-0.14$-0.12-16.67%Miss+53.3%
    Sep 20
    Reported Nov 5
    		$-0.09$0.06-250.00%Miss+65.4%
    Jun 20
    Reported Aug 6
    		$-0.25$-0.01-2400.00%Miss+32.4%
    Mar 20
    Reported May 7
    		$-0.21$-0.28+25.00%Beat+32.3%
    Dec 19
    Reported Mar 12
    		$-0.30$-0.21-42.86%Miss+53.8%
    Sep 19
    Reported Nov 8
    		$-0.26$-0.33+21.21%Beat+63.4%
    Jun 19
    Reported Aug 8
    		$-0.37$-0.30-23.33%Miss+56.0%
    Mar 19
    Reported May 9
    		$-0.31$-0.35+11.43%Beat+56.3%
    Dec 18
    Reported Mar 31
    		$-0.65$-0.70+7.14%Beat+26.1%
    Sep 18
    Reported Nov 8
    		$-0.71$-0.75+5.33%Beat-12.7%
    Jun 18
    Reported Aug 8
    		$-0.84$-0.68-23.53%Miss+1.2%
    Mar 18
    Reported May 9
    		$-0.71$-0.54-31.48%Miss+13.4%
    Dec 17
    Reported Mar 31
    		$-0.88$-0.56-57.14%Miss-14.3%
    Sep 17
    Reported Nov 7
    		$-0.63$-0.87+27.59%Beat-46.5%
    Jun 17
    Reported Aug 11
    		$-0.85$-0.90+5.56%Beat-
    Mar 17
    Reported May 11
    		$-0.82$-1.28+35.94%Beat-
    Dec 16
    Reported Mar 31
    		$-0.77$-0.25-208.00%Miss-
    Sep 16
    Reported Nov 10
    		$-0.43$-0.42-2.38%Miss-

    Key Metrics

    Valuation
    P/E Ratio-2.36EV/EBITDA1.77x
    Price/FCF-3.48xFCF Yield-28.75%
    Profitability
    Profit Margin0.00%Operating Margin-6680.00%
    ROE-7029.00%ROIC180.30%
    Financial Health
    Debt/Equity-0.42xInterest Coverage-3.21x
    Current Ratio7.48xQuick Ratio7.48x
    Trading Statistics
    Beta0.56Avg Volume122.65K
    52-Week High$11.0052-Week Low$5.60

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$9.94
    SMA 20$9.31
    SMA 50$9.08
    SMA 200$7.64
    EMA 10$9.69
    EMA 20$9.41
    EMA 50$8.91
    EMA 200$8.55

    MACD

    Line: 0.36Signal: 0.36Hist: 0.00

    ADX

    ADX: 27.6+DI: 29.2-DI: 17.7

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down8.0
    PSAR$10.85

    Bollinger Bands

    Upper Band$10.80
    Lower Band$7.82
    %B Position3209%(Upper)
    Band Width0.49

    RSI (14-Day)

    Neutral
    50.4

    Momentum Oscillators

    Stoch %K48.1
    Stoch %D60.1
    Williams %R-66.4
    ROC (10d)1.1%
    Momentum0.10
    CCI (20d)-0.2
    MFI (14d)65.0

    Volatility Measures

    ATR (14d)$0.63(6.8%)
    StdDev (20d)0.75
    Hist Vol63.1%(High)

    Volume Flow

    VWAP$9.32
    OBV5.6M
    AD Line-1.5M
    CMF (20d)0.011

    Volume Metrics

    Avg Vol (20d)123.2K
    Vol Ratio0.7x
    VWMA (20d)$9.43

    Pivot Points

    R3$11.34
    R2$10.97
    R1$10.29
    Pivot Point$9.92
    S1$9.23
    S2$8.86
    S3$8.18

    Advanced Oscillators

    TSI20.94
    Ultimate Osc37.9
    KST152.51

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$78,000$947,000$452,000$298,000$1.10M$-759,000$387,000$33.45M$5.84M$8.27M$6.55M
    Cost of Revenue$0$0N/A$0$0$0N/A$0$0$0$122,000$0
    Gross Profit$0$78,000$947,000$452,000$298,000$1.10M$-759,000$387,000$33.45M$5.84M$8.27M$6.55M
    Operating Expenses$29.16M$26.58M$79.59M$21.52M$22.11M$22.99M$25.97M$17.96M$19.69M$19.19M$44.60M$19.62M
    R&D$20.43M$19.46M$14.69M$13.80M$14.87M$14.67M$11.31M$11.40M$12.66M$9.74M$21.85M$13.00M
    SG&A$8.72M$7.11M$8.20M$7.72M$7.24M$8.31M$7.09M$6.56M$7.03M$9.45M$22.04M$6.61M
    Operating Income$-29,155,000$-26,499,000$-78,639,000$-21,066,000$-21,811,000$-21,889,000$-26,731,000$-17,575,000$13.76M$-13,348,000$-36,332,000$-13,065,000
    Interest Income$1.10M$1.03M$1.27M$1.55M$1.75M$2.02M$2.45M$2.57M$1.20M$1.16M$940,000$1.30M
    Interest Expense$852,000$12.68M$23.14M$14.84M$0$0$0$6.86M$213,000$43.98M$153.52M$1.27M
    Income Before Tax$15.77M$-39,179,000$-101,774,000$-35,902,000$15.89M$-17,710,000$-8,916,000$-24,433,000$13.54M$-57,332,000$-189,856,000$-13,042,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$15.77M$-39,182,000$-92,576,000$-35,902,000$15.89M$-17,710,000$-10,253,000$-24,183,000$13.84M$-56,824,000$-177,658,000$-9,002,000
    EBITDA$16.30M$-39,590,000$-102,434,000$-36,844,000$14.73M$-18,569,000$-11,490,000$-26,720,000$12.54M$-58,313,000$-190,524,000$-12,879,000
    EBIT$15.52M$-40,205,000$-103,042,000$-37,450,000$14.14M$-19,725,000$-11,976,000$-27,006,000$12.35M$-58,496,000$-190,796,000$-13,068,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about RNAC

    News

    ETFs Investing in Cartesian Therapeutics, Inc. Stocks

    This article lists several ETFs that invest in Cartesian Therapeutics, Inc. stocks, providing details such as market value, weight, issuer, management style, expense ratio, AUM, price, change, relative volume, and 3-year NAV total return for each fund. The ETFs highlighted include Janus Henderson Small Cap Growth Alpha ETF, iShares Microcap ETF, Invesco NASDAQ Future Gen 200 ETF, and EA Bridgeway Ultra-Small Company Market ETF. The purpose is to show how these funds offer more accessible investment opportunities with lower risk in Cartesian Therapeutics.

    TradingView•8/23/26•
    Neutral

    Wedbush Maintains Cartesian Therapeutics(RNAC.US) With Buy Rating, Maintains Target Price $38

    Wedbush has reiterated its Buy rating for Cartesian Therapeutics (RNAC.US), keeping its target price at $38. This indicates continued confidence in the company's stock performance from the analyst firm.

    Moomoo•8/20/26•
    Bullish

    Wedbush Reiterates Outperform Rating for Cartesian Therapeutics (NASDAQ:RNAC)

    Wedbush reiterated an "Outperform" rating for Cartesian Therapeutics (NASDAQ:RNAC) with a $38 price target, suggesting a significant upside of 314%. The company has a consensus "Moderate Buy" rating from seven analysts, with an average price target of $32.60. Cartesian Therapeutics recently reported strong quarterly earnings of $0.46 EPS, significantly beating analyst expectations of a $0.88 loss.

    MarketBeat•8/18/26•
    Neutral

    RNAC Reiterated by Wedbush -- Rating Maintained at Outperform

    Wedbush analyst Martin Fan has reiterated an 'Outperform' rating for Cartesian Therapeutics Inc (RNAC) with a maintained price target of $38.00, despite the stock being significantly overvalued according to GuruFocus's GF Value™. The company, which is pioneering cell therapy using mRNA technology for autoimmune diseases, has a low GF Score™ of 25/100, reflecting major concerns about its financial health, profitability, and growth prospects, cautioning investors about potential risks.

    GuruFocus•8/18/26•
    Somewhat-Bearish

    Barclays PLC (RNAC) discloses 1.76M-share, 5.99% holding in Cartesian Therapeutics

    Barclays PLC has reported a 5.99% stake in Cartesian Therapeutics Inc. (RNAC), holding 1,760,326 shares of common stock as of June 30, 2026. The filing indicates that Barclays PLC has sole voting power over 1,739,724 shares and shared voting power over 20,602 shares. This disclosure, made via a Schedule 13G filing, details the beneficial ownership and dispositive powers held by Barclays and its subsidiaries over Cartesian Therapeutics' stock.

    Stock Titan•8/13/26•
    Neutral

    Frequently Asked Questions About RNAC

    Does RNAC pay dividends?
    Cartesian Therapeutics Inc. (RNAC) does not currently pay a regular dividend.
    What is RNAC's market cap?
    Cartesian Therapeutics Inc. (RNAC) has a market capitalization of $290.45M with a current stock price of $9.28.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In